Home>Topics>Companies>AstraZeneca

AstraZeneca

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
  1. BRIEF- AstraZeneca's Duaklir Genuair approved in Europe for COPD

    Headlines

    Mon, 24 Nov 2014

    * Duaklir  genuair  approved in european union for chronic obstructive pulmonary disease Source text for Eikon: Further company coverage:

  2. Fitch Downgrades AstraZenaca to 'A+'; Outlook Stable

    Headlines

    Fri, 21 Nov 2014

    the rating agency) LONDON, November 21 (Fitch) Fitch Ratings has downgraded UK-based pharmaceutical AstraZeneca PLC 's ( AstraZeneca ) Long-term Issuer Default Rating (IDR) and senior unsecured rating to 'A+' from 'AA-'. The Outlook

  3. U.S. court overturns bid by India's Ranbaxy to block launch of rival generic drugs

    Headlines

    Thu, 20 Nov 2014

    Nov 20 (Reuters) - A U.S. court has denied a request by Indian drugmaker Ranbaxy Laboratories Ltd to stop competitors from launching copies of AstraZeneca Plc 's heartburn pill Nexium and Roche's antiviral Valcyte, a court filing showed.

  4. New Issue- AstraZeneca prices 750 mln euro 2021 bond

    Headlines

    Wed, 19 Nov 2014

    Underlying govt bond over midswaps, equivalent to 63.5 bp

  5. BRIEF-ADDvise Lab Solutions receives order from AstraZeneca of about SEK 2.4 mln

    Headlines

    Wed, 19 Nov 2014

    * Says receives order from AstraZeneca of about 2.4 million Swedish crowns

  6. UPDATE 3- AstraZeneca trumpets solo strength in cancer drugs, snubbing Pfizer

    Headlines

    Tue, 18 Nov 2014

    * Investor day comes 8 days before Pfizer can resume pursuit

  7. BRIEF- AstraZeneca CEO says "hard to comment" on whether Pfizer will return

    Headlines

    Tue, 18 Nov 2014

    Nov 18 (Reuters) - AstraZeneca executives, speaking to reporters: * CEO says hard to comment on read-across from Pfizer/Merck cancer

  8. Ranbaxy sues FDA over revoking approvals for Nexium, Valcyte copies

    Headlines

    Tue, 18 Nov 2014

    MUMBAI, Nov 18 (Reuters) - Ranbaxy Laboratories Ltd has sued the U.S. Food and Drug Administration (FDA) for revoking approvals granted to the Indian firm to launch copies of two drugs including AstraZeneca Plc 's heartburn pill Nexium, court documents showed.

  9. Neil Woodford says belief in independent AstraZeneca "even stronger"

    Headlines

    Tue, 18 Nov 2014

    LONDON, Nov 18 (Reuters) - AstraZeneca shareholder Neil Woodford said on Tuesday his belief in the drugmaker's independent prospects were now "even stronger" as a result of the firm's strong pipeline of new products.

  10. AstraZeneca trumpets progress in cancer, other drugs

    Headlines

    Tue, 18 Nov 2014

    LONDON, Nov 18 (Reuters) - AstraZeneca , determined to show it has a strong independent future after seeing off a $118 billion bid from Pfizer in May, said it had made good progress in developing a pipeline of new drugs.

« Prev12345Next »
Content Partners